Doctors Revision

Neonatal Apnoea: Recognition, Causes and Complete Management

Text size
On this page

1 Overview

Apnoea — cessation of breathing — is common in newborn infants and ranges from the physiological immaturity of the preterm baby to the first sign of life-threatening sepsis, intracranial haemorrhage or metabolic disease. Because the neonatal brainstem responds to hypoxia and hypercarbia with respiratory depression rather than the adult hyperventilation response, and because the preterm chest wall is so pliable, even healthy preterm infants pause their breathing readily. The clinician’s task is threefold: recognise true apnoea, grade its severity, and find the cause — because apnoea is a symptom, and its treatment is the treatment of what is driving it.

The most common specific syndrome is apnoea of prematurity (AOP) — a developmental disorder of respiratory control in infants born before ~37 weeks that resolves with maturation and is managed supportively. In the term infant, apnoea is far more ominous and demands a search for serious pathology.

2 Learning Objectives

  • Define neonatal apnoea and distinguish central, obstructive and mixed types.
  • Differentiate apnoea of prematurity from periodic breathing and from apnoea signalling underlying disease.
  • List the major causes of apnoea in preterm and term infants and construct a rational investigation plan.
  • Manage an apnoeic infant: stimulation, oxygen/CPAP, caffeine citrate dosing, and treatment of underlying causes.
  • Advise on monitoring, safe sleep and discharge criteria, and recognise a BRUE in the older infant.

3 Definitions and Types of Apnoea

Scroll the table sideways on a smaller screen.

TermDefinitionKey point
ApnoeaCessation of breathing for >20 seconds, or a shorter pause accompanied by bradycardia and/or oxygen desaturationThe 20-second rule is arbitrary; colour/heart-rate change defines significance
Central apnoeaNo respiratory effort — absent chest and abdominal movementFailure of the brainstem respiratory drive; typical of apnoea of prematurity
Obstructive apnoeaRespiratory effort present but airflow absent — chest/abdominal movement without breathUpper-airway collapse (tongue, pharynx, larynx); positional; craniofacial anomalies
Mixed apnoeaCentral pause followed by obstructive componentCommonest pattern overall; central pause lowers tone, airway then collapses
Periodic breathingRegular cycles of 10–15 s breathing with 5–10 s pauses, without bradycardia or desaturationNormal in preterm infants; not apnoea and does not need treatment

A practical classification by timing: apnoea of prematurity (developmental, <37 weeks), apnoea of infancy (term infants, usually pathological — the leading causes are gastro-oesophageal reflux, upper-airway abnormalities and neurological disease), and symptomatic apnoea arising from sepsis, haemorrhage, metabolic or drug effects in any infant.

4 Pathophysiology

Three immaturities converge in the preterm infant:

  • Respiratory-centre immaturity — the medullary chemoreceptors respond to hypoxia with a brief tachypnoea followed by depression and apnoea (the paradoxical neonatal response), and the CO₂ response is blunted. Preterm infants also over-rely on the peripheral chemoreceptors, so cold stress, airway suctioning or even a feeding pause can trigger central apnoea.
  • An exaggerated laryngeal chemoreflex — fluid (milk, saliva) contacting the larynx triggers reflex apnoea, bradycardia and swallowing rather than cough; relevant during feeding.
  • Mechanical disadvantage — the highly compliant chest wall of the preterm infant recoils against diaphragmatic contraction, reducing functional residual capacity and fatiguing respiratory muscles, with airway collapse adding an obstructive component.

External stressors depress the respiratory centre further: sepsis, hypoglycaemia, hypothermia, anaemia, hypoxia and drugs (maternal opioids/sedatives, magnesium sulphate). Intermittent hypoxia from recurrent apnoea is itself harmful — associated with impaired neurodevelopment, so apnoea deserves active treatment rather than passive observation.

5 Causes of Neonatal Apnoea

Scroll the table sideways on a smaller screen.

CategoryExamplesClues
DevelopmentalApnoea of prematurity (immature respiratory centre)Preterm; onset days 2–7; mild, self-limiting episodes
InfectiousSepsis, meningitis, necrotising enterocolitisTemperature instability, feeding intolerance, lethargy, shock
NeurologicalIntraventricular haemorrhage, periventricular leukomalacia, seizures, congenital central hypoventilation, hypoxic-ischaemic encephalopathyAbnormal tone, seizures, bulging fontanelle, severe apnoeas
MetabolicHypoglycaemia, hypocalcaemia, hyponatraemia, severe acidosis, inborn errorsScreen at the bedside; correct rapidly
HaematologicalAnaemia (reduced oxygen delivery)Pallor, tachycardia, poor growth
Airway/structuralUpper-airway obstruction (macroglossia, micrognathia/Pierre Robin, choanal atresia, laryngomalacia), gastro-oesophageal refluxObstructive pattern, positional variation, feeding association
Drugs/toxinsMaternal opioids, sedatives, magnesium; prostaglandin E1 infusionMaternal history; temporal relation to exposure
Temperature/environmentHypothermia, overheatingExamine the care environment

6 Recognition and Assessment

  • Witness and characterise — the episode’s duration, association with feeding or handling, presence of limpness, colour change (central vs peripheral), and any recovery by stimulation alone. Distinguish periodic breathing (no colour/heart-rate change, self-resolving) from true apnoea.
  • Vital signs — bradycardia is the most consistent accompaniment; document oxygen saturation trends from the monitor.
  • Examination — look for the cause: temperature instability, hypotonia, bulging fontanelle, abdominal distension (NEC), pallor (anaemia/sepsis), airway anatomy, signs of reflux.
  • Severity grading — mild (self-resolving with stimulation), moderate (needs stimulation + oxygen), severe (needs bag-mask ventilation/caffeine/CPAP, or is recurrent).

7 Investigations

Directed by the suspected cause, not a blanket panel:

  • Bedside — continuous cardiorespiratory and SpO₂ monitoring with event recording; blood glucose; temperature; a documented seizure assessment.
  • Sepsis work-up — full blood count, C-reactive protein, blood culture; lumbar puncture if meningitis suspected (after stabilisation).
  • Metabolic screen — calcium, sodium, magnesium; consider ammonia/lactate and metabolic profiling for recurrent severe apnoea, especially in term infants.
  • Imaging — cranial ultrasound for intraventricular haemorrhage in preterm infants; consider MRI/EEG if seizures or encephalopathy; chest imaging if obstructive features.
  • Blood gas — acidosis and CO₂ retention support a severe or obstructive component.
  • Polysomnography — reserved for puzzling recurrent obstructive apnoea or suspected congenital central hypoventilation.

8 Management

Immediate steps during an episode

  1. Stimulate — flick the foot/rub the back; most mild apnoeas resolve with tactile stimulation.
  2. Open the airway, position, give oxygen — head-neutral positioning (avoid over-extension which obstructs the preterm airway); begin free-flow oxygen for persistent desaturation.
  3. Bag-mask ventilation — if apnoea persists or bradycardia is severe; check for reversible obstruction and hypoglycaemia while ventilating.
  4. Escalate — recurrent severe episodes need CPAP or intubation and a full aetiological work-up.

Specific therapy

  • Caffeine citrate (first-line pharmacotherapy for apnoea of prematurity) — a methylxanthine that increases central respiratory drive and chemoreceptor sensitivity.
  • CPAP — 4–6 cm H₂O splints the airway and improves functional residual capacity; effective for mixed/obstructive components and reduces apnoea frequency.
  • Correct the cause — antibiotics for sepsis, glucose for hypoglycaemia, transfusion for significant anaemia, treat seizures and reflux as appropriate.

Scroll the table sideways on a smaller screen.

ParameterDoseNotes
Loading dose20 mg/kg (caffeine citrate) IV or oral, onceIV preferred if absorption uncertain; the citrate salt = half caffeine base
Maintenance5–10 mg/kg/day once dailyStart 24 h after the load; titrate to apnoea frequency
Side effectsTachycardia, jitteriness, feeding intolerance, rare seizures at toxicityCheck levels if refractory or renal impairment; well tolerated overall
DurationUsually until ~34–37 weeks’ corrected age, weaning as apnoeas ceaseDiscontinue before discharge if apnoea-free; many units stop 5–7 days before planned discharge

Do not routinely give methylxanthines or CPAP to term infants — find and treat the cause.

9 Monitoring and Discharge

  • Hospital — cardiorespiratory + SpO₂ monitoring in all infants with significant apnoea; treat and observe until apnoea-free on a stable caffeine dose (or weaned).
  • Discharge criteria — commonly: apnoea-free for a defined period (e.g. 5–7 days) off caffeine and off respiratory support, gaining weight, and feeding adequately.
  • Home cardiorespiratory monitors — no evidence that routine home monitoring prevents sudden infant death; reserve for exceptional circumstances (e.g. tracheostomy, congenital central hypoventilation) under specialist guidance.
  • Safe sleep counselling — supine position, firm flat surface, no soft bedding, no smoking exposure, avoid overheating; this applies to every infant, and especially to siblings of infants who have had apnoeas or SIDS.
  • Family education — teach caregivers stimulation response and basic resuscitation where risk is ongoing; ensure clear escalation pathways and follow-up.

10 Apnoea Beyond the Neonatal Unit: BRUE

In infants past the neonatal period, the 2016 American Academy of Pediatrics term brief resolved unexplained event (BRUE) replaced the older “apparent life-threatening event (ALTE)”. A BRUE is an event in an infant <1 year, witnessed by a caregiver, lasting <1 minute and characterised by one or more of: apnoea, colour change (cyanosis or pallor), change in muscle tone, choking or gagging — after which the infant returns to baseline and remains well.

  • Low-risk BRUE — age >60 days, born ≥32 weeks and corrected age ≥45 weeks, event <1 min, first event, no CPR needed: manage with reassurance, examination and education; no routine testing.
  • Higher-risk BRUE — age ≤60 days, prematurity, event ≥1 min, recurrence, or need for stimulation/CPR: observe with monitoring, consider brief work-up (glucose, ECG ± further tests as guided), and arrange close follow-up.

11 Viva & Exam Points

  • Definition — breathing pause >20 s, or any pause with bradycardia/desaturation; periodic breathing is normal.
  • Types — central (no effort), obstructive (effort, no airflow), mixed; mixed is commonest.
  • Preterm vs term — apnoea of prematurity is developmental and treated with caffeine ± CPAP; term apnoea means sepsis, haemorrhage, metabolic disease or airway pathology until excluded.
  • Caffeine — load 20 mg/kg, maintenance 5–10 mg/kg/day; treat until apnoea-free, usually ~34–37 weeks corrected age.
  • Immediate care — stimulate → position/oxygen → bag-mask ventilation → find the cause.
  • BRUE — witnessed, <1 min, self-resolving, infant back to baseline; low-risk needs reassurance, high-risk needs observation/work-up.
  • Safe sleep — supine, firm surface, smoke-free — counsel every family.

12 References

For education only. Apply current Uganda Clinical Guidelines and local protocols when managing patients.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top